Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of GCA as classified according to protocol-specified criteria;~* Participants entering Period 1 must be receiving treatment with TCZ 8 mg/kg IV Q4W.~Exclusion Criteria:~* Treatment with any other investigational agent besides TCZ within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to screening;~* Evidence of serious uncontrolled disease;~* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections;~* Active TB requiring treatment within the previous 3 years.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCZ IV Q4W (Type: EXPERIMENTAL): Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.

Based on this trial design, predict the completion outcome and termination type (if applicable).